Administration of recombinant human R-Spo1 protected Lgr5+ ISCs and Paneth cells against GVHD, resulting in maintenance of the integrity of the gut mucosa and intestinal commensals after murine allogeneic SCT4,9. The gene discussed is RSPO1; the disease is graft versus host disease.